Search Results

The NxStage PureFlow SL module is an optional accessory to the NxStage System One that prepares dialysate for use during hemodialysis, as prescribed by the physician.

The NxStage PFSL module is an optional accessory to the NxStage System One that is used to treat water for hemodialysis per ANSI/AAMI/ISO 13959:2009 and ANSI/AAMI/ISO 26722:2009 and proportion it with dialysate concentrate to produce dialysate per ANSI/AAMI/ISO 11663:2009. The PFSL module consists of the Control Unit (CU), the water Pre-Treatment Unit, the optional OPTA Kit, the Purification Pack (PAK), and the Dialysate Sack (SAK) with Dialysate Concentrate.

Here's a breakdown of the acceptance criteria and study information for the NxStage PureFlow SL Subsystem, based on the provided text:

1. Table of Acceptance Criteria and Reported Device Performance

2. Sample Size Used for the Test Set and Data Provenance

• Sample Size: Not explicitly stated. The document mentions "validation batches of dialysate" were used for testing.
• Data Provenance: The study was conducted by NxStage Medical, Inc., with manufacturing occurring in Fresnillo, Zacatecas, Mexico. The context suggests this was an internal validation study to support a device modification. The study is retrospective in the sense that it evaluates the modified device's performance against established standards, but it's prospective for the testing itself to confirm the extended MTU time.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts

• This type of study does not involve human expert adjudication for image interpretation or diagnosis. The ground truth is established via objective laboratory measurements against defined standards.

4. Adjudication Method

• Not applicable. This is a technical performance study, not a diagnostic accuracy study relying on human interpretation.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Status

• Not applicable. This is a performance validation study for a medical device's technical specifications, not a comparative effectiveness study involving human readers and AI. The device is a "proportioning hemodialysis system and accessories," not an AI diagnostic tool.

6. Standalone Performance Study Status

• Yes, a standalone performance study was done. The document states: "Performance and verification and validation testing was conducted to characterize performance of the proposed device. This included stability, bioburden and endotoxin testing on validation batches of dialysate to support the extension of the MTU duration to 96-hours." This refers to testing the device itself, without human intervention in the performance evaluation.

7. Type of Ground Truth Used

• Objective laboratory measurements and compliance with industry standards: The ground truth for bioburden and endotoxin levels was established by laboratory testing of dialysate samples and comparison against the specific limits set by ANSI/AAMI/ISO 11663:2009. The MTU duration extension was validated through stability testing.

8. Sample Size for the Training Set

• Not applicable. This device is not an AI/ML model that requires a "training set" in the traditional sense. It's a hardware device with defined performance parameters.

9. How the Ground Truth for the Training Set Was Established

• Not applicable, as there is no training set for an AI/ML model. The "ground truth" (i.e., the acceptable performance criteria) for the device's technical specifications was established by recognized industry standards (ANSI/AAMI/ISO 11663:2009, ANSI/AAMI/ISO 13959:2009, and ANSI/AAMI/ISO 26722:2009).

Ask a specific question about this device